Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 1/20 | 0.41 |
| ▸ | TPI1 | P60174 | 2/20 | 0.39 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.37 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.37 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.37 |
| ▸ | PGK1 | P00558 | 1/20 | 0.37 |
| ▸ | PGK2 | P07205 | 1/20 | 0.37 |
| ▸ | FDPS | P14324 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | PGD | P52209 | 2/20 | 0.34 |
| ▸ | MPI | P34949 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16041590 | 0.92 | FBP1 (0.37) | FBP1TPI1LPAR3LPAR2LPAR1 | |
| SCHEMBL135753 | 0.86 | FBP1 (0.37) | FBP1TPI1LPAR3LPAR2LPAR1 | |
| SCHEMBL133396 | 0.86 | FBP1 (0.37) | FBP1TPI1LPAR3LPAR2LPAR1 | |
| SCHEMBL6413988 | 0.86 | LPAR3 (0.43) | FBP1TPI1LPAR3LPAR2LPAR1 | |
| SCHEMBL23777275 | 0.86 | FBP1 (0.37) | FBP1TPI1LPAR3LPAR2LPAR1 | |
| SCHEMBL24909875 | 0.85 | FBP1 (0.33) | FBP1TPI1LPAR3LPAR2LPAR1 | |
| Hydrochloric Acid SCHEMBL4602688 | 0.84 | S1PR1 (0.36) | FBP1TPI1LPAR3LPAR2LPAR1 | |
| SCHEMBL23633124 | 0.84 | FBP1 (0.35) | FBP1TPI1LPAR3LPAR2LPAR1 | |
| SCHEMBL6684306 | 0.84 | FBP1 (0.35) | FBP1TPI1LPAR3LPAR2LPAR1 | |
| Ammonia Solution, Strong SCHEMBL5467104 | 0.84 | S1PR1 (0.36) | FBP1TPI1LPAR3LPAR2LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117757239-B | High-performance, low-smoke density and low-heat release rate polycarbonate composition and preparation method thereof | 上海品诚控股集团有限公司 | 2024-09-03 | — | — | CN | disclosed |
| CN-117757239-A | High-performance, low-smoke density and low-heat release rate polycarbonate composition and preparation method thereof | 上海品诚控股集团有限公司 | 2024-03-26 | — | — | CN | disclosed |
| EP-4086306-B1 | CABLE COMPONENT INCLUDING A HALOGEN-FREE FLAME RETARDANT COMPOSITION | CORNING RES & DEV CORP (US) | 2024-02-28 | — | — | EP | disclosed |
| CN-117050595-A | Flame-retardant acrylic emulsion and preparation method thereof | 江苏生达新材料科技有限公司 | 2023-11-14 | — | — | CN | disclosed |
| US-11732195-B2 | Cable component including a halogen-free flame retardant composition | CORNING RESEARCH & DEVELOPMENT CORPORATION (US) | 2023-08-22 | — | — | US | disclosed |
| US-20230017490-A1 | STING INHIBITORS AND THEIR THERAPEUTIC USES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2023-01-19 | — | — | US | disclosed |
| EP-4086306-A1 | CABLE COMPONENT INCLUDING A HALOGEN-FREE FLAME RETARDANT COMPOSITION | Corning Research & Development Corporation (US) | 2022-11-09 | — | — | EP | disclosed |
| EP-3717563-B1 | CABLE COMPONENT INCLUDING A HALOGEN-FREE FLAME RETARDANT COMPOSITION | CORNING RES & DEV CORP (US) | 2022-08-03 | — | — | EP | disclosed |
| EP-3717563-A1 | CABLE COMPONENT INCLUDING A HALOGEN-FREE FLAME RETARDANT COMPOSITION | Corning Research & Development Corporation (US) | 2020-10-07 | — | — | EP | disclosed |
| US-20200270527-A1 | CABLE COMPONENT INCLUDING A HALOGEN-FREE FLAME RETARDANT COMPOSITION | CORNING RESEARCH & DEVELOPMENT CORPORATION | 2020-08-27 | — | — | US | disclosed |
| US-20170239182-A1 | PHARMACEUTICAL FORMULATIONS OF AND METHODS TO PREPARE CHELATING AGENTS FOR EFFICIENT METAL REMOVAL TREATMENT SYSTEMS | HAYES MARK E (US) | 2017-08-24 | — | — | US | disclosed |
| US-20170231910-A1 | PHARMACEUTICAL FORMULATIONS OF CHELATING AGENTS AS A METAL REMOVAL TREATMENT SYSTEM | HAYES MARK E (US) | 2017-08-17 | — | — | US | disclosed |
| US-20170128366-A1 | PHARMACEUTICAL FORMULATIONS OF CHELATING AGENTS AS A METAL REMOVAL TREATMENT SYSTEM | ZONEONE PHARMA INC (US) | 2017-05-11 | — | — | US | disclosed |
| WO-2016025559-A1 | PHARMACEUTICAL FORMULATIONS OF AND METHODS TO PREPARE CHELATING AGENTS FOR EFFICIENT METAL REMOVAL TREATMENT SYSTEMS | ZONEONE PHARMA, INC. (US) | 2016-02-18 | — | — | WO | disclosed |
| WO-2016025611-A2 | PHARMACEUTICAL FORMULATIONS OF CHELATING AGENTS AS A METAL REMOVAL TREATMENT SYSTEM | ZONEONE PHARMA, INC. (US) | 2016-02-18 | — | — | WO | disclosed |
| WO-2014153192-A1 | PHARMACEUTICAL FORMULATIONS OF CHELATING AGENTS AS A METAL REMOVAL TREATMENT SYSTEM | ZONEONE PHARMA, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20140271825-A1 | PHARMACEUTICAL FORMULATIONS OF CHELATING AGENTS AS A METAL REMOVAL TREATMENT SYSTEM | ZONEONE PHARMA, INC. | 2014-09-18 | — | — | US | disclosed |
| US-20140142052-A1 | PHOSPHORYLATED POLYOLS, PYROPHOSPHATES, AND DERIVATIVES THEREOF HAVING BIOLOGICAL ACTIVITY | NORMOXYS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142052-A1 | PHOSPHORYLATED POLYOLS, PYROPHOSPHATES, AND DERIVATIVES THEREOF HAVING BIOLOGICAL ACTIVITY | PPIP5K2, PHOSPHO1, PIK3CA | FBP1 128/4885TPI1 193/4885LPAR3 987/4885 |
| US-20230017490-A1 | STING INHIBITORS AND THEIR THERAPEUTIC USES | STING1, CGAS, MAVS | FBP1 2746/4885TPI1 712/4885LPAR3 1064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.